De Motu Cordis (DMC) receives a letter of support from Food Allergy Research and Education (FARE)
November 1, 2024
On November 1, 2024, DMC received a formal letter of support from Food Allergy Research and Education (FARE), the largest nonprofit organisation in the U.S. committed to enhancing the quality of life and health for individuals with food allergies through innovative research, education, and advocacy.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
